Mount TAM Biotechnologies, Inc. (MNTM) financial statements (2021 and earlier)
Company profile
| Business Address |
7250 REDWOOD BLVD, SUITE 300 NOVATO, CA 94945 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 21 - Tobacco Products (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 58 | 46 | 375 | 5 | 3 | |||
| Cash and cash equivalents | 58 | 46 | 375 | 5 | 3 | |||
| Receivables | 300 | 300 | ||||||
| Inventory, net of allowances, customer advances and progress billings | (5) | |||||||
| Inventory | (5) | |||||||
| Prepaid expense | 5 | 4 | 4 | |||||
| Other undisclosed current assets | (300) | (300) | (0) | 5 | ||||
| Total current assets: | 62 | 50 | 380 | 5 | 3 | |||
| Noncurrent Assets | ||||||||
| Other undisclosed noncurrent assets | 2 | 7 | ||||||
| Total noncurrent assets: | 2 | 7 | ||||||
| TOTAL ASSETS: | 64 | 57 | 380 | 5 | 3 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 852 | 927 | 603 | 400 | 170 | |||
| Accounts payable | 464 | 457 | 335 | 278 | 90 | |||
| Accrued liabilities | 95 | 283 | 145 | 65 | ||||
| Employee-related liabilities | 200 | 130 | 93 | 57 | ||||
| Interest and dividends payable | 93 | 39 | 20 | |||||
| Other undisclosed accounts payable and accrued liabilities | 1 | 18 | 9 | 80 | ||||
| Debt | 1,332 | 694 | 18 | 18 | 18 | |||
| Due to related parties | 254 | |||||||
| Total current liabilities: | 2,184 | 1,621 | 620 | 671 | 187 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 554 | |||||||
| Long-term debt, excluding current maturities | 554 | |||||||
| Total noncurrent liabilities: | 554 | |||||||
| Other undisclosed liabilities | 115 | |||||||
| Total liabilities: | 2,184 | 1,621 | 1,174 | 786 | 187 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (2,120) | (1,565) | (794) | (781) | (185) | |||
| Common stock | 6 | 5 | 5 | 4 | 1 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (0) | (0) | (0) | (0) | ||||
| Common stock, value, subscriptions | 58 | 43 | ||||||
| Additional paid in capital | 6,852 | 5,580 | 3,677 | 1,526 | 775 | |||
| Accumulated deficit | (8,978) | (7,150) | (4,534) | (2,353) | (960) | |||
| Other undisclosed stockholders' equity attributable to parent | (0) | |||||||
| Total stockholders' equity: | (2,120) | (1,565) | (794) | (781) | (185) | |||
| TOTAL LIABILITIES AND EQUITY: | 64 | 57 | 380 | 5 | 3 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 1 | 1 | |||||
| Revenue, net | ✕ | ✕ | 1 | ||||
| Other income | 1 | ✕ | |||||
| Cost of revenue (Cost of Goods and Services Sold) | (5) | ||||||
| Gross profit: | 1 | (5) | |||||
| Operating expenses | (1,817) | (2,531) | (2,079) | (2,087) | (146) | ||
| Other operating expense, net (Other Expenses) | (8) | ||||||
| Other undisclosed operating loss | (1) | ||||||
| Operating loss: | (1,817) | (2,531) | (2,079) | (2,095) | (150) | ||
| Interest and debt expense | (55) | (19) | (14) | (66) | (0) | ||
| Loss from continuing operations before equity method investments, income taxes: | (1,871) | (2,550) | (2,093) | (2,161) | (150) | ||
| Other undisclosed income from continuing operations before income taxes | 44 | ||||||
| Loss before gain (loss) on sale of properties: | (1,828) | (2,550) | (2,093) | (2,161) | (150) | ||
| Other undisclosed net loss | (66) | (87) | |||||
| Net loss: | (1,828) | (2,616) | (2,181) | (2,161) | (150) | ||
| Other undisclosed net income attributable to parent | 66 | ||||||
| Net loss available to common stockholders, diluted: | (1,828) | (2,616) | (2,181) | (2,095) | (150) | ||
Comprehensive Income ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (1,828) | (2,616) | (2,181) | (2,161) | (150) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,828) | (2,616) | (2,181) | (2,161) | (150) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.